window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

orphan drug designation

  • Cardiovascular diseases,Clinical Trials,Rare Diseases

    Rare Disease Day 2026: Cereno Scientific advances disease-modifying therapies in PAH

    As Rare Disease Day 2026 shines a spotlight on patients [...]

    February 27, 2026
  • Cardiovascular diseases,Clinical Trials,Rare Diseases,Research & Development

    Cereno Scientific completes expanded access program milestone for CS1 in pulmonary arterial hypertension

    Cereno Scientific has completed the last patient’s last visit in [...]

    February 4, 2026
  • Orphan drugs,Rare Diseases,Regulatory Affairs

    EMA grants orphan drug designation to Kedrion treatment for congenital aceruloplasminemia

    Kedrion has received orphan drug designation from the European Medicines [...]

    November 27, 2025
  • Cell & Gene Therapy,Oncology,Orphan drugs,Regulatory Affairs

    Minovia Therapeutics gains FDA orphan drug designation for MNV-201 in myelodysplastic syndrome

    Minovia Therapeutics has received orphan drug designation from the US [...]

    October 17, 2025
  • Drug Development,Neurosciences,Rare Diseases,Regulatory Affairs

    SOM Biotech secures EMA orphan designation opinion for Huntington’s drug SOM3355

    Barcelona-based biotech advances Huntington’s programme as EMA backs orphan designation, [...]

    September 15, 2025
  • Clinical Trials,Drug Development,Rare Diseases

    Cereno taps global CRO for next big step in pulmonary hypertension drug trial

    Selection of CRO marks key milestone in advancing CS1 as [...]

    July 7, 2025
  • Biologics & Biosimilars,Clinical Trials,Drug Development,Rare Diseases

    Eleva doses first volunteers with new therapy targeting rare kidney disease

    Dosing of CPV-104 in healthy volunteers marks key milestone in [...]

    July 7, 2025
  • Biologics & Biosimilars,Clinical Trials,Patient Centricity

    Poolbeg receives FDA Orphan Drug Designation for POLB 001

    Poolbeg Pharma has been granted Orphan Drug Designation (ODD) by [...]

    May 27, 2025
  • Clinical Trials,Drug Development

    Kaerus receives dual FDA designations for lead Fragile X candidate

    Kaerus Bioscience has been granted Orphan Drug Designation and Rare [...]

    May 19, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top